Gemtuzumab Ozogamicin
This product is an antibody–drug conjugate (ADC) consisting of a recombinant humanized anti-CD33 monoclonal antibody specifically linked to the cytotoxic antibiotic calicheamicin. It specifically targets the CD33 antigen, which is expressed on leukemic blasts and immature normal cells of the myeloid lineage. Upon binding, the complex is internalized and calicheamicin is released, specifically inducing DNA double-strand breaks and apoptosis.
Key Features and Benefits
-
Targeted Therapy: Directs cytotoxic activity to CD33-positive cells, reducing off-target damage.
-
Monoclonal Antibody Component: Humanized anti-CD33 antibody for selective binding.
-
Potent Cytotoxic Payload: Calicheamicin induces DNA strand breaks, triggering apoptosis.
-
Clinical Use: Approved for the treatment of acute myeloid leukemia (AML) in adults and pediatric patients.
-
Combination Therapy: Can be used as monotherapy or in combination with conventional chemotherapy.
Applications
-
Acute Myeloid Leukemia (AML): Treatment of newly diagnosed and relapsed/refractory CD33-positive AML.
-
Research & Development: Model ADC for studying targeted delivery of cytotoxins.
-
Combination Studies: Evaluation in combination regimens for enhanced AML treatment outcomes.
Storage and Handling
-
Storage: Lyophilized vials should be stored refrigerated at 2–8 °C.
-
Handling: Reconstitute with sterile water for injection; protect from light; follow institutional guidelines for handling cytotoxic agents.
Gemtuzumab ozogamicin exemplifies targeted ADC therapy, specifically combining antibody specificity with a powerful cytotoxic drug to improve therapeutic efficacy in AML patients.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.